Core Viewpoint - The announcement by Hutchison China MediTech regarding the acceptance of the new drug application for Fruquintinib for advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusion or rearrangement has been prioritized for review by the National Medical Products Administration of China [1] Company Summary - Hutchison China MediTech has developed Fruquintinib, a novel selective oral inhibitor targeting FGFR1, 2, and 3 [1] - The drug is aimed at adult patients who have previously undergone systemic treatment and have specific genetic markers related to their cancer [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been on the rise, with a five-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement, indicating a specific target population for Fruquintinib [1]

Market Overview - The Hong Kong stock market showed a positive trend in the morning session on December 30, with the Hang Seng Index rising by 0.44% to 25,749.19 points, the Hang Seng Tech Index increasing by 1.04% to 5,540.17 points, the National Enterprises Index up by 0.67% to 8,950.95 points, and the Red Chip Index gaining 0.33% to 4,033.69 points [1] Sector Performance - Major technology stocks experienced gains, with Alibaba up by 0.7%, Tencent Holdings increasing by 0.42%, JD Group rising by 1.25%, Xiaomi up by 0.73%, NetEase increasing by 1.3%, Meituan rising by 0.19%, Kuaishou up by 0.08%, and Bilibili increasing by 0.21% [1] - The semiconductor sector showed strong performance, led by InnoCare, with the leading company SMIC rising over 3% [1] - Oil stocks were among the top gainers, with CNOOC increasing by over 4% [1] - The non-ferrous metals sector rebounded collectively, while wind power stocks saw significant declines, and gaming stocks continued to drop [1] New Listings - Six new stocks were listed on the Hong Kong market today, with InnoCare seeing a substantial increase of over 35% [1] Corporate News - China Energy Construction (03996.HK) won a bid for an ecological comprehensive governance project in Shaanxi Province, with a total contract value of 6.864 billion RMB, covering various construction aspects with a total duration of 36 months [2] - China Shenhua (01088.HK) announced that its second phase generator unit has officially commenced commercial operation after a 168-hour trial run, with the fourth unit expected to be operational by February 2026 [2] - Bay Area Development (00737.HK) signed a construction contract worth 775 million RMB with Poly Longda [3] - China Railway Construction (01186.HK) completed the issuance of 4.45 billion RMB in corporate bonds [4] - Sichuan Energy Investment Development (01713.HK) entered into a strategic cooperation agreement with Mengsheng Electronics to deepen collaboration in the power industry [5] - China Supply Chain Industry (03708.HK) signed a data center agreement with Shuwi Technology [6] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for SYH2069 injection in China [6] - Hutchison China MediTech (00013.HK) announced that its new drug application for HMPL-453 for intrahepatic cholangiocarcinoma has been accepted for priority review [6] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a phase 1 clinical study of HLX37 for advanced/metastatic solid tumors [6] - Henxin Technology (01085.HK) announced that its planned 350MW solar thermal power station is ready to commence construction [7] - Runhua Services (02455.HK) expanded its property management services to multiple provinces in western China [8] - Hong Kong Industrial International (00480.HK) plans to sell its entire issued share capital of Yue Shan Limited for 452 million HKD [9] - Yimei International Holdings (01870.HK) received formal approval for its 218MW electrochemical independent energy storage project in Guangdong [9] Institutional Insights - Huatai Securities noted that the asset performance has been volatile this year, with frequent style and sector rotations, leading to decreased clarity in investment behavior [10] - CITIC Securities highlighted the recent appreciation of the RMB, which benefits RMB-denominated equity assets, and expects stable macro-financial conditions to support bank operating environments [10] - Founder Securities reported on the central economic work conference and the Ministry of Finance's optimization of "two new" policies, indicating that national subsidies will continue into 2026 [11]

Market Overview - The Hong Kong stock market opened higher on December 30, with the Hang Seng Index rising by 1.17 points to 25,636.4 points, the Hang Seng Tech Index increasing by 20.6 points (0.38%) to 5,503.61 points, and the National Enterprises Index up by 10.74 points (0.12%) to 8,902.45 points [1] - Major tech stocks showed mixed performance, with Tencent Holdings up 0.34%, JD Group up 0.8%, while NetEase, Meituan, and Kuaishou fell by 0.56%, 0.19%, and 0.55% respectively [1] - Chip stocks opened higher, with InnoCare Pharma rising over 4%, while automotive stocks generally increased, with NIO up over 5% [1] - Gold stocks declined, with Zijin Mining International dropping over 2% [1] - Six new stocks were listed today, with InnoCare rising by 45.5%, Meilian Holdings by 15.63%, Wuyi Vision by 14.75%, Linqingxuan by 9.3%, while Xunce and Woan Robotics remained flat [1] Corporate News - China Energy Construction (03996.HK) announced that its subsidiary won a bid for an ecological comprehensive governance project in Shaanxi Province, with a total contract value of 6.864 billion RMB, covering watershed management, infrastructure, urban renewal, water conservancy, and environmental protection works, with a total construction period of 36 months [2] - China Shenhua (01088.HK) reported that its Phase II Unit 3 generator set in Qingyuan has passed a 168-hour trial run and is now in commercial operation, while Unit 4 is under construction and expected to be operational by February 2026 [2] - Bay Area Development (00737.HK) signed a construction contract with Poly Longda for a total price of 775 million RMB [3] - China Railway Construction (01186.HK) completed the issuance of 4.45 billion RMB in corporate bonds [4] - Sichuan Energy Investment Development (01713.HK) entered into a strategic cooperation agreement with Mengsheng Electronics to deepen collaboration in the field of data intelligence in the power industry [5] - China Supply Chain Industry (03708.HK) signed a "Test Version Data Center Agreement" with Shuwei Technology [6] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for GLP-1/GIP receptor dual agonist peptide injection (SYH2069) in China [6] - Hutchison China MediTech (00013.HK) announced that the new drug application for Frengratin (HMPL-453) for second-line treatment of intrahepatic cholangiocarcinoma has been accepted and included in priority review [6] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase I clinical study of HLX37 in patients with advanced/metastatic solid tumors [6] - Hengxin Technology (01085.HK) announced that its planned 350MW solar thermal power station is ready to commence construction [7] - Runhua Services (02455.HK) expanded its property management services to multiple provinces in western China [8] - Hong Kong International Industries (00480.HK) plans to sell its entire issued share capital of Yue Shan Limited for 452 million HKD [9] - Yimei International Holdings (01870.HK) received formal approval from Guangdong Power Grid for the "Shaoguan City Lechang 218MW 436MWh electrochemical independent energy storage project" [9] Institutional Insights - Huatai Securities noted that this year's asset performance has been volatile, with frequent style and industry rotations, leading to decreased clarity in main lines and a right-side investment behavior [10] - CITIC Securities highlighted the recent appreciation of the RMB, which benefits the performance of RMB-denominated equity assets, and indicated that the central bank will use policy tools more flexibly, focusing on domestic demand targets [10] - The outlook for 2026 suggests stable macro-financial conditions pointing to a stable banking operating environment, with expectations for bank interest margins to bottom out and income and profit recovery in the real sector [11] - The absolute return logic for the industry comes from the re-evaluation of systemic risks in the banking sector, driving valuation recovery and stable equity return characteristics attracting capital inflows [11] - Founder Securities reported that the Central Economic Work Conference and the Ministry of Finance have clarified the optimization of "two new" policies, with multiple regions selecting old-for-new platform enterprises [11]

Company News - China Energy Construction (03996.HK) announced that its subsidiary consortium won the bid for the ecological comprehensive治理 project in the Henghe and Yuehe river basins in Ankang City, Shaanxi Province [6] - China Shenhua (01088.HK) reported that the No. 3 generator unit of the Qingyuan Phase II project has passed the 168-hour trial operation and is officially in commercial operation, while the construction of the No. 4 generator unit is progressing steadily, with plans for operation in February 2026 [7] - Hutchison Whampoa (00013.HK) announced that the new drug application for Fanzhuo Grelatin for second-line treatment of intrahepatic cholangiocarcinoma has been accepted and included in priority review in China [8] - SenseTime (00020.HK) completed the placement of 1.75 billion new Class B shares [9] - UBTECH (09880.HK) Chairman Zhou Jian committed not to reduce holdings within 12 months, while China Petroleum (00857.HK) received an increase of 30 million A-shares and 11.896 million H-shares from its controlling shareholder, China Petroleum Group [10] - Yujian (02432.HK) proposed a plan for A-share listing on the Shenzhen Stock Exchange [11] Industry News - The paper industry, cryptocurrency-related stocks, and the new energy vehicle sector showed collective strength, while gold, lithium battery, and electric power stocks generally retreated [5]

Core Viewpoint - The article highlights the journey of Gao Haiyan, a coal mine owner, who transitioned from a career in academia and corporate to becoming a coal entrepreneur, driven by a strong sense of national and familial responsibility [2][3]. Group 1: Background and Early Life - Gao Haiyan grew up in a family with a strong sense of national identity and initially aspired to be a doctor due to her childhood health issues. A pivotal moment during her youth made her realize the importance of money and the need to improve rural education [5][6]. - She pursued economics at East China Normal University, motivated by her father's influence and the belief that understanding economic principles was essential for achieving her dreams [6]. Group 2: Career Development - In the early 1990s, Gao moved to Hong Kong to study its economy and later worked with Hutchison Whampoa, where she helped facilitate investments in mainland China [7]. - After a decade in Hong Kong, she was encouraged to return to her hometown to invest in local infrastructure, which eventually led her to take over a failing state-owned coal mine in 2003 [8][9]. Group 3: Challenges and Setbacks - The People's Coal Mine, which Gao took over, was heavily indebted and faced operational challenges, with an annual production capacity of only 150,000 tons [11][12]. - Gao faced significant legal and operational hurdles, including a contentious partnership with a foreign investor that led to a prolonged legal battle over ownership rights [13][17]. Group 4: Recovery and Growth - After years of legal disputes, Gao regained control of the coal mine in 2016, and by 2021, the mine was able to resume operations, achieving a production capacity of 1.2 million tons per year [24]. - The mine implemented advanced mining techniques and achieved profitability in a favorable market environment, allowing Gao to fulfill her commitments to employees and stakeholders [24][25]. Group 5: Current Challenges and Future Outlook - Since 2023, the coal market has faced significant downturns, with prices dropping sharply, leading to increased operational pressures on the mine [26]. - Gao is diversifying her investments into technology and education sectors to create a stable funding source for her philanthropic initiatives, indicating a potential exit from the coal industry [26][27]. - The mine faces additional challenges, including community safety concerns and tax liabilities, which could threaten its financial viability [27].

Core Viewpoint - The announcement by Hutchison China MediTech Limited (00013.HK) regarding the acceptance of the new drug application for Fanregratinib (HMPL-453) by the National Medical Products Administration of China highlights a significant advancement in the treatment options for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusion or rearrangement [1] Company Summary - Hutchison China MediTech Limited has received acceptance for its new drug application for Fanregratinib, a selective oral inhibitor targeting FGFR1, 2, and 3, specifically for adult patients with advanced, metastatic, or unresectable ICC who have previously undergone systemic therapy [1] - The drug application has been prioritized for review by the National Medical Products Administration, indicating its potential significance in the market [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been on the rise, with a five-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement, indicating a specific target population for Fanregratinib [1]

Core Viewpoint - The new drug application for Fanregratinib (HMPL-453) for adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) has been accepted by the National Medical Products Administration of China and is prioritized for review [1] Company Summary - Hutchison China MediTech Limited (和黄医药) announced the acceptance of the new drug application for Fanregratinib, a selective oral inhibitor targeting FGFR1, 2, and 3 [1] - The drug is aimed at patients who have previously undergone systemic treatment and have FGFR2 fusion or rearrangement [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been steadily increasing, with a 5-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement [1] Research Summary - A Phase II registration study conducted in China, which was single-arm, multicenter, and open-label, provided data supporting the new drug application [1] - The study achieved the primary endpoint of objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), and overall survival (OS) also supporting the primary findings [1] - Complete study data is expected to be presented at an upcoming academic conference [1]

Core Viewpoint - The new drug application for Fanregratinib (HMPL-453) for the treatment of advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) in adult patients has been accepted by the National Medical Products Administration of China and is included in priority review [1] Company Summary - Hutchison China MediTech Limited (和黄医药) announced the acceptance of the new drug application for Fanregratinib, a selective oral inhibitor targeting FGFR1, 2, and 3 [1] - The drug is aimed at patients who have previously received systemic treatment and have FGFR2 fusion or rearrangement [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been on the rise, with a 5-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement [1] Research Summary - A Phase II registration study conducted in China, which was a single-arm, multicenter, open-label trial, provided data supporting the new drug application [1] - The study achieved the primary endpoint of objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), and overall survival (OS) also supporting the primary findings [1] - Complete study data is expected to be presented at an upcoming academic conference [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ― 僅次於肝細胞癌的第二大常見肝癌類型，長期生存率一般相對較差 ― 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈凡瑞格拉替尼 （fanregratinib ，HMPL-453） 用於既往接受過系統性治療，且具有成纖維細胞生長因子受體（「FGFR」）2融合或重排的晚期、轉移性或不可手 術切除的肝內膽管癌（ICC）成人患者的新藥上市申請已獲中國國家藥品監督管理局（「國家藥監局」）受理 ，並獲 納入優先審評。 凡瑞格拉替尼是一種新型、選擇性的FGFR1 、2和3口服抑制劑。肝內膽管癌是一種起源於肝內膽管上皮的具有高度 侵襲性的惡性腫瘤，佔原發性肝癌的約8.2%至15.0% ，是繼肝細胞癌之後第二常見的肝癌類型。近年來，肝內膽管 癌發病率呈持續上升趨勢，5年總生存率約9%。1 全球肝內膽管癌患者中約有10-15％伴有FGFR2融合或重排。2,3 一項在中國開展的單臂、多中心、開放標 ...

Core Viewpoint - Yantian International Container Terminal is a crucial hub for global trade, showcasing China's economic vitality and serving as a model for high-quality development in logistics and industry [4][7][17]. Development - Yantian International is recognized as the preferred port for ultra-large vessels in South China and is one of the largest container terminals globally, handling an average of one container every two seconds [4][8]. - The terminal has evolved from a small port with a throughput of 100,000 TEUs to a world-class port with over 15 million TEUs, significantly contributing to Guangdong's foreign trade [7][8]. - The port's operations are enhanced by advanced digital systems, allowing for intelligent management of logistics, resulting in industry-leading operational efficiency [9]. Environmental Initiatives - Yantian has implemented green port initiatives, including a significant shift to electric power and shore power systems, leading to a notable reduction in carbon emissions [10]. - The terminal has been recognized as the "Global Best Green Container Terminal" multiple times, highlighting its commitment to sustainable practices [10]. Connectivity - Yantian International is developing a comprehensive transportation network that connects domestic and international markets, enhancing the resilience of the Greater Bay Area's economy [11][12]. - The port facilitates rapid import and export processes, exemplified by the "Cherry Express" service that ensures fresh produce reaches consumers quickly [12]. Service Innovation - The terminal supports the transformation of Chinese manufacturing by providing tailored logistics solutions for high-value products, including electric vehicles and cultural creative products [14][15]. - Yantian has become a key channel for China's "new three samples" (electric vehicles, lithium batteries, solar cells) to enter international markets, addressing logistical challenges through innovative shipping solutions [15][16]. Future Outlook - Yantian is positioned to evolve from a traditional logistics hub to a center for marine economy innovation and green shipping, aligning with national strategies for maritime strength [17].